Interpreting Expression Data with Metabolic Flux Models: Predicting Mycobacterium tuberculosis Mycolic Acid Production

Metabolism is central to cell physiology, and metabolic disturbances play a role in numerous disease states. Despite its importance, the ability to study metabolism at a global scale using genomic technologies is limited. In principle, complete genome sequences describe the range of metabolic reactions that are possible for an organism, but cannot quantitatively describe the behaviour of these reactions. We present a novel method for modeling metabolic states using whole cell measurements of gene expression. Our method, which we call E-Flux (as a combination of flux and expression), extends the technique of Flux Balance Analysis by modeling maximum flux constraints as a function of measured gene expression. In contrast to previous methods for metabolically interpreting gene expression data, E-Flux utilizes a model of the underlying metabolic network to directly predict changes in metabolic flux capacity. We applied E-Flux to Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB). Key components of mycobacterial cell walls are mycolic acids which are targets for several first-line TB drugs. We used E-Flux to predict the impact of 75 different drugs, drug combinations, and nutrient conditions on mycolic acid biosynthesis capacity in M. tuberculosis, using a public compendium of over 400 expression arrays. We tested our method using a model of mycolic acid biosynthesis as well as on a genome-scale model of M. tuberculosis metabolism. Our method correctly predicts seven of the eight known fatty acid inhibitors in this compendium and makes accurate predictions regarding the specificity of these compounds for fatty acid biosynthesis. Our method also predicts a number of additional potential modulators of TB mycolic acid biosynthesis. E-Flux thus provides a promising new approach for algorithmically predicting metabolic state from gene expression data.

[1]  William R Bishai,et al.  Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. , 2008, The Journal of antimicrobial chemotherapy.

[2]  J N Fain,et al.  Effects of menadione and vitamin K 5 on glucose metabolism, respiration, lipolysis, cyclic 3',5'-adenylic acid accumulation, and adenyl cyclase in white fat cells. , 1971, Molecular pharmacology.

[3]  Gang Wu,et al.  Integrative Analysis of Transcriptomic and Proteomic Data: Challenges, Solutions and Applications , 2007, Critical reviews in biotechnology.

[4]  Gurdyal S Besra,et al.  The methyl-branched fortifications of Mycobacterium tuberculosis. , 2002, Chemistry & biology.

[5]  Roger E Bumgarner,et al.  Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. , 2001, Science.

[6]  B. Palsson,et al.  Regulation of gene expression in flux balance models of metabolism. , 2001, Journal of theoretical biology.

[7]  B. Palsson,et al.  Stoichiometric flux balance models quantitatively predict growth and metabolic by-product secretion in wild-type Escherichia coli W3110 , 1994, Applied and environmental microbiology.

[8]  B. Palsson,et al.  Transcriptional regulation in constraints-based metabolic models of Escherichia coli Covert , 2002 .

[9]  Kazuyuki Shimizu,et al.  Metabolic flux analysis based on 13C-labeling experiments and integration of the information with gene and protein expression patterns. , 2004, Advances in biochemical engineering/biotechnology.

[10]  Shigeo Abe DrEng Pattern Classification , 2001, Springer London.

[11]  Markus J. Herrgård,et al.  Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.

[12]  Gang Wu,et al.  Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. , 2006, Biochemical and biophysical research communications.

[13]  David G. Stork,et al.  Pattern Classification , 1973 .

[14]  J D Coleman,et al.  Trends in the incidence of tuberculosis in possums and livestock, associated with differing control intensities applied to possum populations , 2006, New Zealand veterinary journal.

[15]  T. Myers,et al.  The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism , 2004, Journal of Biological Chemistry.

[16]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[17]  Bernhard O. Palsson,et al.  Context-Specific Metabolic Networks Are Consistent with Experiments , 2008, PLoS Comput. Biol..

[18]  S. Klamt,et al.  GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism , 2007, Genome Biology.

[19]  Vishwanath Venketaraman,et al.  Glutathione and growth inhibition of Mycobacterium tuberculosis in healthy and HIV infected subjects , 2006, AIDS research and therapy.

[20]  A. Regev,et al.  Distinct physiological states of Plasmodium falciparum in malaria-infected patients , 2007, Nature.

[21]  Nagasuma R. Chandra,et al.  Flux Balance Analysis of Mycolic Acid Pathway: Targets for Anti-Tubercular Drugs , 2005, PLoS Comput. Biol..

[22]  P. Berche,et al.  A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis , 1997, Antimicrobial agents and chemotherapy.

[23]  J. T. Crawford,et al.  ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates , 2003, Antimicrobial Agents and Chemotherapy.

[24]  E. Winzeler,et al.  Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Nancy D. Connell,et al.  Characterization of a Glutathione Metabolic Mutant of Mycobacterium tuberculosis and Its Resistance to Glutathione and Nitrosoglutathione , 2006, Journal of bacteriology.

[26]  D. Young,et al.  Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. , 1993, Trends in microbiology.

[27]  E. Muñoz-Elías,et al.  Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence , 2006, Molecular microbiology.

[28]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[29]  W. Bishai,et al.  Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. , 1999, The Journal of antimicrobial chemotherapy.

[30]  Paul Carroll,et al.  The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis , 2007, Proceedings of the National Academy of Sciences.

[31]  Gary A. Churchill,et al.  Analysis of Variance for Gene Expression Microarray Data , 2000, J. Comput. Biol..

[32]  Vojo Deretic,et al.  Mechanisms of action of isoniazid , 2006, Molecular microbiology.

[33]  U. Alon,et al.  Just-in-time transcription program in metabolic pathways , 2004, Nature Genetics.

[34]  J C Sacchettini,et al.  Mechanisms for isoniazid action and resistance. , 2008, Novartis Foundation symposium.

[35]  J Gowrishankar,et al.  Why is transcription coupled to translation in bacteria? , 2004, Molecular microbiology.

[36]  G. M. Rodríguez,et al.  Control of iron metabolism in Mycobacterium tuberculosis. , 2006, Trends in microbiology.

[37]  G. Besra,et al.  Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis , 2005, Clinical Microbiology Reviews.

[38]  J S Blanchard,et al.  Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. , 2002, Current pharmaceutical biotechnology.

[39]  Gang Wu,et al.  Correlation of mRNA Expression and Protein Abundance Affected by Multiple Sequence Features Related to Translational Efficiency in Desulfovibrio vulgaris: A Quantitative Analysis , 2006, Genetics.

[40]  Alfred Nordheim,et al.  Comparative proteome analysis of Staphylococcus aureus biofilm and planktonic cells and correlation with transcriptome profiling , 2006, Proteomics.

[41]  Bernhard O. Palsson,et al.  Metabolic flux balance analysis and the in silico analysis of Escherichia coli K-12 gene deletions , 2000, BMC Bioinformatics.

[42]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[43]  Bernhard O. Palsson,et al.  Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets , 2007 .

[44]  Nir Friedman,et al.  Tissue classification with gene expression profiles , 2000, RECOMB '00.

[45]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Xavier Charpentier,et al.  MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. , 2002, Microbiology.

[47]  Galina V. Glazko,et al.  A Multivariate Extension of the gene Set Enrichment Analysis , 2007, J. Bioinform. Comput. Biol..

[48]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[49]  E. Muñoz-Elías,et al.  Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence , 2005, Nature Medicine.

[50]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[51]  B. Palsson,et al.  Saccharomyces cerevisiae phenotypes can be predicted by using constraint-based analysis of a genome-scale reconstructed metabolic network , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.

[53]  K. Reynolds,et al.  Biosynthetic origins of the natural product, thiolactomycin: a unique and selective inhibitor of type II dissociated fatty acid synthases. , 2003, Journal of the American Chemical Society.

[54]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[55]  William R. Jacobs,et al.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis , 2000, Nature Medicine.

[56]  R J Heath,et al.  Lipid biosynthesis as a target for antibacterial agents. , 2001, Progress in lipid research.

[57]  Stephen S Fong,et al.  Metabolic gene–deletion strains of Escherichia coli evolve to computationally predicted growth phenotypes , 2004, Nature Genetics.

[58]  B. Palsson,et al.  In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data , 2001, Nature Biotechnology.

[59]  Yang Liu,et al.  Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages , 2003, The Journal of experimental medicine.